Toxicokinetic modeling and its applications in chemical risk assessment
- PMID: 12559690
- DOI: 10.1016/s0378-4274(02)00375-2
Toxicokinetic modeling and its applications in chemical risk assessment
Abstract
In recent years physiologically based pharmacokinetic (PBPK) modeling has found frequent application in risk assessments where PBPK models serve as important adjuncts to studies on modes of action of xenobiotics. In this regard, studies on mode of action provide insight into both the sites/mechanisms of action and the form of the xenobiotic associated with toxic responses. Validated PBPK models permit calculation of tissue doses of xenobiotics and metabolites for a variety of conditions, i.e. at low-doses, in different animal species, and in different members of a human population. In this manner, these PBPK models support the low-dose and interspecies extrapolations that are important components of current risk assessment methodologies. PBPK models are sometimes referred to as physiological toxicokinetic (PT) models to emphasize their application with compounds causing toxic responses. Pharmacokinetic (PK) modeling in general has a rich history. Data-based PK compartmental models were developed in the 1930's when only primitive tools were available for solving sets of differential equations. These models were expanded in the 1960's and 1970's to accommodate new observations on dose-dependent elimination and flow-limited metabolism. The application of clearance concepts brought many new insights about the disposition of drugs in the body. In the 1970's PBPK/PT models were developed to evaluate metabolism of volatile compounds of occupational importance, and, for the first time, dose-dependent processes in toxicology were included in PBPK models in order to assess the conditions under which saturation of metabolic and elimination processes lead to non-linear dose response relationships. In the 1980's insights from chemical engineers and occupational toxicology were combined to develop PBPK/PT models to support risk assessment with methylene chloride and other solvents. The 1990's witnessed explosive growth in risk assessment applications of PBPK/PT models and in applying sensitivity and variability methods to evaluate model performance. Some of the compounds examined in detail include butadiene, styrene, glycol ethers, dioxins and organic esters/aids. This paper outlines the history of PBPK/PT modeling, emphasizes more recent applications of PBPK/TK models in health risk assessment, and discusses the risk assessment perspective provided by modern uses of these modeling approaches.
Similar articles
-
PBPK models in risk assessment--A focus on chloroprene.Chem Biol Interact. 2007 Mar 20;166(1-3):352-9. doi: 10.1016/j.cbi.2007.01.016. Epub 2007 Feb 8. Chem Biol Interact. 2007. PMID: 17324392
-
Development of physiologically based pharmacokinetic and physiologically based pharmacodynamic models for applications in toxicology and risk assessment.Toxicol Lett. 1995 Sep;79(1-3):35-44. doi: 10.1016/0378-4274(95)03355-o. Toxicol Lett. 1995. PMID: 7570672 Review.
-
Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment.J Toxicol Environ Health. 1997 Dec 26;52(6):475-515. doi: 10.1080/00984109708984077. J Toxicol Environ Health. 1997. PMID: 9397182
-
Applications of physiologic pharmacokinetic modeling in carcinogenic risk assessment.Environ Health Perspect. 1994 Dec;102 Suppl 11(Suppl 11):37-50. doi: 10.1289/ehp.94102s1137. Environ Health Perspect. 1994. PMID: 7737040 Free PMC article. Review.
-
Physiologically-based pharmacokinetic and toxicokinetic models in cancer risk assessment.J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2005;23(1):31-53. doi: 10.1081/GNC-200051856. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2005. PMID: 16291521 Review.
Cited by
-
The need for a new toxicity testing and risk analysis paradigm to implement REACH or any other large scale testing initiative.Arch Toxicol. 2007 May;81(5):385-7. doi: 10.1007/s00204-006-0175-0. Epub 2007 Jan 30. Arch Toxicol. 2007. PMID: 17262219 Free PMC article. No abstract available.
-
The application of global sensitivity analysis in the development of a physiologically based pharmacokinetic model for m-xylene and ethanol co-exposure in humans.Front Pharmacol. 2015 Jun 30;6:135. doi: 10.3389/fphar.2015.00135. eCollection 2015. Front Pharmacol. 2015. PMID: 26175688 Free PMC article.
-
Studying permethrin exposure in flight attendants using a physiologically based pharmacokinetic model.J Expo Sci Environ Epidemiol. 2013 Jul;23(4):416-27. doi: 10.1038/jes.2013.12. Epub 2013 Mar 6. J Expo Sci Environ Epidemiol. 2013. PMID: 23462847 Free PMC article.
-
Physiologically based synthetic models of hepatic disposition.J Pharmacokinet Pharmacodyn. 2006 Dec;33(6):737-72. doi: 10.1007/s10928-006-9031-3. Epub 2006 Oct 19. J Pharmacokinet Pharmacodyn. 2006. PMID: 17051440
-
Screening of the antileishmanial and antiplasmodial potential of synthetic 2-arylquinoline analogs.Sci Rep. 2023 Oct 16;13(1):17523. doi: 10.1038/s41598-023-43805-4. Sci Rep. 2023. PMID: 37845281 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources